greeksoup/ stock research

Omeros Corp.: Q1 FY2026 earnings call

What management said about Q1 FY2026, from the documents filed with the SEC on 13 May 2026: press release. Guidance figures: 3 new, 1 kept. The quarter’s numbers.

Key takeaways

  • Net income positive on derivative gain: Net income was $56.1 million, or $0.78 per share basic, against a $33.5 million loss a year earlier. Diluted EPS was $0.62. Source
  • Adjusted net loss narrowed: Excluding the derivative change, non-GAAP adjusted net loss was $17.1 million, or $0.24 per share, against $33.4 million, or $0.58 per share, a year earlier. Source
  • Launch sales began in January: Gross product sales were $11.1 million and net sales were $9.9 million, after wholesaler distribution fees and chargebacks. Source
  • Permanent J-code assigned in April: CMS assigned a permanent J-code for YARTEMLEA, effective July 1, 2026, which management said simplifies billing and reimbursement across payors. Source
  • Operating expenses fell on zaltenibart sale: Total operating expenses were $27.3 million, against $35.0 million a year earlier. The decline is attributed to reduced OMS906 research after the Novo Nordisk deal. Source
  • OMS527 path to clinic being streamlined: NIDA funds OMS527 for cocaine use disorder. After an FDA request for more nonclinical data, the company is working to streamline the path to an in-patient trial. Source
  • Primate study reported safety results: A February 2026 nonhuman primate study reported a reduction in myeloid progenitor cells of up to 99% after one course, with no safety signals observed. Source
  • Cash and investments of $135.3 million: Cash and short-term investments were $135.3 million at March 31, 2026, after the February repayment of the remaining 2026 Notes. Source
  • 2029 Notes are the only debt: The 2029 Notes, with $70.8 million principal, are the only debt outstanding and mature in June 2029. Source

“The launch of YARTEMLEA has changed the trajectory of Omeros, both operationally and financially,”

Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief Executive Officer

Guidance

AreaPeriodFigureAgainst last quarter
YARTEMLEA reimbursement code (J-code) SourceEffective July 1, 2026July 1, 2026New
New Technology Add-On Payment (NTAP) SourceFinal rule August 2026; effective October 1, 2026effective October 1, 2026New
EU marketing authorization decision for YARTEMLEA SourceMid-2026mid-2026Kept
OMS527 in-patient clinical trial start SourceBy year-end 2026by year-end 2026New

What changed from last quarter

  • New: CMS assigned a permanent J-code specific to YARTEMLEA in April. Source
  • Guidance kept: The EMA decision timing for YARTEMLEA stayed at mid-2026. Source
  • New guidance: A year-end 2026 start target was given for the OMS527 in-patient trial. Source
  • Ended: The remaining 2026 convertible notes were repaid at maturity in February 2026. Source
  • New: The company repurchased and retired about 0.4 million shares in the quarter. Source
  • New: A drug development candidate was selected for the MASP-2 small-molecule program. Source
  • New: The company is finalizing an indication for a Phase 2 program for OMS1029. Source

Results and growth drivers

  • Net income positive on derivative gain: Net income was $56.1 million, or $0.78 per share basic, against a $33.5 million loss a year earlier. Diluted EPS was $0.62. Source
  • Non-cash derivative gain included: Results include a $73.1 million non-cash gain from marking to market the embedded derivatives on the 2029 Notes. Source
  • Adjusted net loss narrowed: Excluding the derivative change, non-GAAP adjusted net loss was $17.1 million, or $0.24 per share, against $33.4 million, or $0.58 per share, a year earlier. Source
  • Discontinued operations added income: Income from discontinued operations, net of tax, was $4.8 million, or $0.07 per share, compared with $4.1 million, or $0.07 per share, a year earlier. Source

YARTEMLEA launch and sales

  • Launch sales began in January: Gross product sales were $11.1 million and net sales were $9.9 million, after wholesaler distribution fees and chargebacks. Source
  • Revenue booked on wholesaler sales: Revenue for the period reflects sales of YARTEMLEA to U.S. wholesalers. Source
  • Early adoption cited at transplant centers: Management cited early adoption across transplant centers, expanding formulary access and reimbursement support. Source

“The progress achieved this quarter further demonstrates the strength of our science and the value we are creating across Omeros.”

Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief Executive Officer

Reimbursement and regulatory milestones

  • Permanent J-code assigned in April: CMS assigned a permanent J-code for YARTEMLEA, effective July 1, 2026, which management said simplifies billing and reimbursement across payors. Source
  • EU review decision expected mid-2026: The marketing authorization application is under EMA review, with a decision expected in mid-2026. Approval would cover all EU member states and EEA countries. Source

Operating costs and non-operating items

  • Operating expenses fell on zaltenibart sale: Total operating expenses were $27.3 million, against $35.0 million a year earlier. The decline is attributed to reduced OMS906 research after the Novo Nordisk deal. Source
  • Administrative costs rose modestly: Selling, general and administrative expense was $13.4 million, against $11.1 million a year earlier. Cost of product sales was $0.6 million. Source
  • Interest expense rose on 2029 Notes: Interest expense, net, was $5.9 million against $3.7 million, mainly from the 2029 Notes, partly offset by the repaid 2026 Notes. Source
  • Interest income higher on cash: Interest and other income was $1.5 million, against $1.1 million a year earlier, reflecting higher cash and investment balances. Source

MASP-2 and complement programs

  • MASP-2 small-molecule candidate selected: A drug development candidate was selected for the MASP-2 small-molecule program, which is advancing to IND-enabling studies. Source
  • OMS1029 Phase 2 indication pending: The company is finalizing an indication for a Phase 2 program for OMS1029, its long-acting MASP-2 antibody. Source
  • More YARTEMLEA indications under assessment: Management is assessing YARTEMLEA across lectin pathway indications, including ARDS, sickle cell disease, acute kidney injury, solid organ transplant-related TMA and delayed graft function. Source

Oncology, addiction and anti-infective programs

  • OMS527 path to clinic being streamlined: NIDA funds OMS527 for cocaine use disorder. After an FDA request for more nonclinical data, the company is working to streamline the path to an in-patient trial. Source
  • OncotoX-AML candidate chosen: A drug development candidate has been selected for OncotoX-AML, with IND-enabling studies underway. The lead indication is acute myeloid leukemia. Source
  • Primate study reported safety results: A February 2026 nonhuman primate study reported a reduction in myeloid progenitor cells of up to 99% after one course, with no safety signals observed. Source
  • T-CAT manuscript accepted for publication: The manuscript describing the T-CAT antibody platform, aimed at multidrug-resistant organisms, was accepted for publication. Source

Capital, cash and debt

  • Cash and investments of $135.3 million: Cash and short-term investments were $135.3 million at March 31, 2026, after the February repayment of the remaining 2026 Notes. Source
  • 2029 Notes are the only debt: The 2029 Notes, with $70.8 million principal, are the only debt outstanding and mature in June 2029. Source
  • Shares repurchased in first quarter: About 0.4 million shares were repurchased and retired for an aggregate $4.2 million. Source
  • Derivative liability declined: The non-current embedded derivative liability on the 2029 Notes was $84.0 million, against $157.2 million at December 31, 2025. Source

Strategy and partnership

  • Novo Nordisk deal described as strengthening: Management said the Novo Nordisk transaction strengthened the balance sheet and accelerated pipeline advancement, including next-generation MASP-2 programs. Source
  • Zaltenibart rights held by Novo Nordisk: Novo Nordisk acquired global rights to zaltenibart (formerly OMS906), an inhibitor of MASP-3, under an asset purchase and licensing agreement. Source
  • Pipeline includes OMS527 and antibodies: The company describes OMS527 as fully funded by NIDA and its pipeline as including antibodies for multidrug-resistant organisms and oncology programs. Source

Coming up, as management said on 13 May 2026

  • EMA decision on YARTEMLEA: A decision from the European Medicines Agency is expected in mid-2026. Approval would authorize marketing in EU and EEA countries. Source
  • J-code takes effect July 1: The permanent J-code for YARTEMLEA becomes effective on July 1, 2026. Source
  • NTAP final rule in August: Management expects the CMS final rule on NTAP in August, with NTAP effective October 1, 2026. Source
  • OMS527 in-patient trial start: The company is working with FDA to start the in-patient trial of OMS527 by year-end 2026. Source
  • OMS1029 Phase 2 indication selection: The company is finalizing the indication for a Phase 2 program for OMS1029. Source

Figures management reported

FigureReported
YARTEMLEA gross and net product sales Source$11.1 million gross; $9.9 million net
Research and development expense Source$13.4 million, against $23.8 million
OncotoX-AML nonhuman primate result SourceUp to 99% reduction in myeloid progenitor cells

Risks management discussed

  • Regulatory: FDA requested additional nonclinical information on OMS527, and the company is working to streamline the path to the in-patient trial. Source

Earlier plans management reported on

  • Met: The remaining $17.1 million of 2026 Notes was repaid at maturity in February 2026, as planned. Source
  • Not stated: The prior release said a meeting with FDA was scheduled for the coming quarter; this release describes a subsequent meeting on the request. Source
  • Not stated: The prior release expected publication in the coming weeks; this release says the manuscript was accepted for publication. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.